Literature DB >> 8365193

Tightening the clinical trial.

J W Tukey1.   

Abstract

Randomized clinical trials adhere more closely to pre-agreed-on protocols than almost any other type of experiment, yet we can tighten up their analysis if we desire. If we convert the analysis into a randomization analysis--where the one set of data is analyzed many times--once as though each acceptable assignment has been employed, we can eliminate any dependence of the analysis on statistical or probabilistic assumptions. To do this effectively when many assignments could be acceptable, we can go to double randomization, in which a subset, usefully kept balanced, of acceptable assignments is selected (perhaps randomly) before data acquisition. If we have one covariate, adjustment for which answers a question that is at least as appropriate, we can easily build on this. Imperfect covariance adjustments can help almost as much as perfect ones. If it is appropriate to work with many covariate(s), it is often desirable to first construct a (few) compound covariate(s) and then work with it (them). Often we can base the coefficients in our compound covariate on the univariate regressions of response on single covariates. Doing this within each arm of the trial and pooling keeps the fitting of the final adjustment unbiased. Since we can prespecify how the compounds are to be calculated and fitted, we can do all this while retaining rigid prespecification. Prespecification, randomization, and intelligent use of covariates combined to make the resulting significance analysis of platinum standard quality. (If we want confidence statements, as we ordinarily should, it may make sense, for technical reasons, to plan for somewhat less than platinum standard quality).

Entities:  

Mesh:

Year:  1993        PMID: 8365193     DOI: 10.1016/0197-2456(93)90225-3

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  23 in total

1.  Trimming, weighting, and grouping SNPs in human case-control association studies.

Authors:  J Hoh; A Wille; J Ott
Journal:  Genome Res       Date:  2001-12       Impact factor: 9.043

2.  A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression.

Authors:  Janete M Cerutti; Rosana Delcelo; Marcelo João Amadei; Claudia Nakabashi; Rui M B Maciel; Bercedis Peterson; Jennifer Shoemaker; Gregory J Riggins
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

3.  Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer.

Authors:  Pinar B Yildiz; Yu Shyr; Jamshedur S M Rahman; Noel R Wardwell; Lisa J Zimmerman; Bashar Shakhtour; William H Gray; Shuo Chen; Ming Li; Heinrich Roder; Daniel C Liebler; William L Bigbee; Jill M Siegfried; Joel L Weissfeld; Adriana L Gonzalez; Mathew Ninan; David H Johnson; David P Carbone; Richard M Caprioli; Pierre P Massion
Journal:  J Thorac Oncol       Date:  2007-10       Impact factor: 15.609

Review 4.  Mass spectrometry-based proteomic profiling of lung cancer.

Authors:  Sebahat Ocak; Pierre Chaurand; Pierre P Massion
Journal:  Proc Am Thorac Soc       Date:  2009-04-15

5.  Generated effect modifiers (GEM's) in randomized clinical trials.

Authors:  Eva Petkova; Thaddeus Tarpey; Zhe Su; R Todd Ogden
Journal:  Biostatistics       Date:  2016-07-27       Impact factor: 5.899

6.  Proteomic patterns of preinvasive bronchial lesions.

Authors:  S M Jamshedur Rahman; Yu Shyr; Pinar B Yildiz; Adriana L Gonzalez; Huiming Li; Xueqiong Zhang; Pierre Chaurand; Kiyoshi Yanagisawa; Bonnie S Slovis; Robert F Miller; Mathew Ninan; York E Miller; Wilbur A Franklin; Richard M Caprioli; David P Carbone; Pierre P Massion
Journal:  Am J Respir Crit Care Med       Date:  2005-09-22       Impact factor: 21.405

Review 7.  Current sample size conventions: flaws, harms, and alternatives.

Authors:  Peter Bacchetti
Journal:  BMC Med       Date:  2010-03-22       Impact factor: 8.775

8.  Developing and validating continuous genomic signatures in randomized clinical trials for predictive medicine.

Authors:  Shigeyuki Matsui; Richard Simon; Pingping Qu; John D Shaughnessy; Bart Barlogie; John Crowley
Journal:  Clin Cancer Res       Date:  2012-08-27       Impact factor: 12.531

9.  Smoking-related genomic signatures in non-small cell lung cancer.

Authors:  Pierre P Massion; Yong Zou; Heidi Chen; Aixiang Jiang; Peter Coulson; Christopher I Amos; Xifeng Wu; Ignacio Wistuba; Qingyi Wei; Yu Shyr; Margaret R Spitz
Journal:  Am J Respir Crit Care Med       Date:  2008-09-05       Impact factor: 21.405

10.  Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer.

Authors:  J Joshua Smith; Natasha G Deane; Fei Wu; Nipun B Merchant; Bing Zhang; Aixiang Jiang; Pengcheng Lu; J Chad Johnson; Carl Schmidt; Christina E Bailey; Steven Eschrich; Christian Kis; Shawn Levy; M Kay Washington; Martin J Heslin; Robert J Coffey; Timothy J Yeatman; Yu Shyr; R Daniel Beauchamp
Journal:  Gastroenterology       Date:  2009-11-13       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.